Compare HQI & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HQI | PRQR |
|---|---|---|
| Founded | 2002 | 2012 |
| Country | United States | Netherlands |
| Employees | 75000 | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 232.1M | 262.5M |
| IPO Year | 2008 | 2014 |
| Metric | HQI | PRQR |
|---|---|---|
| Price | $17.73 | $1.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $19.00 | $7.78 |
| AVG Volume (30 Days) | 25.4K | ★ 923.4K |
| Earning Date | 11-12-2026 | 11-17-2026 |
| Dividend Yield | ★ 1.44% | N/A |
| EPS Growth | ★ 73.08 | N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $30,640,000.00 | N/A |
| Revenue This Year | $0.54 | $8.25 |
| Revenue Next Year | $5.47 | N/A |
| P/E Ratio | $53.68 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.38 | $1.20 |
| 52 Week High | $20.84 | $2.49 |
| Indicator | HQI | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 45.91 | 41.38 |
| Support Level | $15.28 | $1.37 |
| Resistance Level | $18.49 | $1.99 |
| Average True Range (ATR) | 0.98 | 0.10 |
| MACD | -0.09 | 0.02 |
| Stochastic Oscillator | 34.17 | 56.67 |
HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The company's primary source of revenue is royalty fees based on the operation of its franchised offices.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.